Tirzepatide vs Semaglutide vs Retatrutide
Semaglutide targets GLP-1 receptors; tirzepatide targets GIP and GLP-1 receptors; retatrutide targets GIP, GLP-1 and glucagon receptors. They are distinct engineered molecules, with different trial populations and development histories. More receptor targets do not automatically establish greater efficacy or safety.
This article compares identifiable published experiments and trial results. Retatrutide now has published phase 3 findings but remains investigational in those current publications. A research preparation must be identified separately from the pharmaceutical products or trial formulations.
Quick Comparison Table
The table below summarizes the principal published characteristics of the three compounds. All values are reproduced from peer-reviewed pharmacology literature and registered clinical-trial publications, not from product marketing material.
| Attribute | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Originator | Novo Nordisk | Eli Lilly | Eli Lilly |
| Receptor targets | GLP-1 | GIP + GLP-1 | GLP-1 + GIP + glucagon |
| First approved (clinical) | 2017 | 2022 | Phase 3 (not approved) |
| Plasma half-life | ~7 days | ~5 days | ~6 days (Phase 1 estimate) |
| Pivotal trial program | SUSTAIN, STEP | SURPASS, SURMOUNT | TRIUMPH |
All three compounds are subcutaneous injectables in their registered or trialed forms (semaglutide additionally has an oral formulation). The table is a factual research summary; expanded mechanism, pharmacokinetic, and trial detail follows in the sections below.
Mechanism: Three Approaches to Incretin Signaling
The three compounds have different receptor-target profiles. They are distinct engineered molecules, rather than semaglutide sequentially modified into tirzepatide and retatrutide. The original design papers describe each molecule’s sequence, acylation and receptor assays; receptor count alone does not explain a clinical result.
Mono-agonism: GLP-1 only (Semaglutide)
Semaglutide is a 31-amino-acid analog of native glucagon-like peptide-1 (GLP-1), with two amino acid substitutions (Aib at position 8, Arg at position 34, using native GLP-1 residue numbering) and a C18 fatty diacid attached via a glutamic acid spacer to lysine-26. The fatty acid modification promotes reversible albumin binding and prolonged exposure; the Aib substitution at position 8 protects against DPP-4 degradation. Semaglutide selectively activates the GLP-1 receptor (GLP-1R) - a class B Gαs-coupled receptor expressed on pancreatic β-cells, hypothalamic neurons, and the gastrointestinal tract - and elicits classical GLP-1R signaling: cAMP elevation, PKA and EPAC2 activation, glucose-dependent insulin secretion, glucagon suppression in hyperglycemic states, and delayed gastric emptying. The mechanism was characterized extensively by Lau and colleagues at Novo Nordisk (Lau et al. 2015, J Med Chem).
Dual agonism: GLP-1 + GIP (Tirzepatide)
Tirzepatide is a 39-amino-acid synthetic peptide engineered by Eli Lilly that combines structural elements of native glucose-dependent insulinotropic polypeptide (GIP) with GLP-1-like substitutions, plus a C20 fatty diacid for albumin binding. Tirzepatide is described by Coskun et al. (2018, Mol Metab) as a 'dual GIP and GLP-1 receptor agonist', with imbalanced potency - somewhat higher activity at GIP-R than GLP-1R in cell-based assays. The historical research rationale for adding GIP agonism, articulated in the Coskun mechanism paper and earlier dual-agonist literature (Finan et al. 2013, Sci Transl Med), is that GIPR and GLP-1R are distinct receptors with overlapping β-cell signaling, including cAMP, and potentially complementary effects, and that GIP signaling on adipocytes may complement GLP-1's central appetite effects in published metabolic models.
Triple agonism: GLP-1 + GIP + glucagon (Retatrutide)
Retatrutide (LY3437943) is a 39-residue synthetic peptide adding glucagon receptor agonism to the GIP/GLP-1 dual profile. Coskun et al. (2022, Cell Metab) reported balanced GCGR and GLP-1R activity but greater GIPR activity in vitro. The published research rationale for adding glucagon agonism is the historical observation that joint glucagon/GLP-1 receptor activation reduced food intake and increased whole-body energy expenditure in the tested rodent models (Day et al. 2009, Nat Chem Biol). Combining glucagon agonism with GLP-1 agonism - which suppresses glucagon's hyperglycemic effects via insulinotropic action - was theorized to dissociate glucagon's metabolic from glycemic effects in research-model contexts.
Synthesis: A Research-Design Progression
Mono-, dual- and triple-receptor agonism provide a useful comparison of research strategies. They do not make these three compounds a single molecular lineage, or show that a later trial percentage was caused by adding one receptor. Sequence design, receptor balance, acylation, exposure and trial population must each be considered. Researchers studying multi-receptor agonism in vitro may find a research-grade triple-agonist comparator useful; the GLP-3 catalogue listing links to our partner's retatrutide. Match the supplied material and lot report to the experiment.
Pharmacokinetics & Half-Life Comparison
All three compounds rely on fatty-acid-mediated albumin binding to extend plasma exposure beyond the minutes-scale half-life of native GLP-1 (~2 minutes) and native GIP (~5-7 minutes). The following PK values belong to specified clinical formulations and studies.
Semaglutide has a plasma half-life of approximately 7 days in human research studies, supporting once-weekly subcutaneous dosing in registered protocols (injectable semaglutide label, section 5.2). The C18 diacid linker confers strong but reversible albumin binding (>99%), and clearance is primarily via proteolytic degradation rather than renal excretion. The authorised oral product uses SNAC to facilitate predominantly gastric absorption. Oral bioavailability depends on formulation and study conditions; the approximately 1% estimate for some strengths of the cited oral semaglutide formulation is not universal across oral semaglutide products.
Tirzepatide has a plasma half-life of approximately 5 days in human research studies (Coskun et al. 2018; clinical tirzepatide label, section 5.2), also supporting once-weekly subcutaneous administration. The C20 diacid imparts albumin binding similar in magnitude to semaglutide's, and disposition is similarly proteolytic. The cited sources describe subcutaneous formulations; they do not establish an oral tirzepatide product.
Retatrutide Phase 1 PK data, reported by Urva et al. (2022, Lancet) and Coskun et al. (2022, Cell Metab), describe a plasma half-life of approximately 6 days with dose-proportional exposure and once-weekly subcutaneous suitability. The PK profile is consistent with the design intent of matching the dosing cadence of earlier-generation incretin agonists. An approved label would require a separate regulatory decision; phase 3 completion does not guarantee one.
The convergent ~5-7 day half-life across all three compounds reflects shared design constraints - albumin binding strong enough to extend exposure across a week, but reversible enough to permit clearance - rather than receptor pharmacology per se.
Published Research Timeline
2021 - STEP-1: semaglutide was studied in a placebo-controlled obesity trial.
2021 - SURPASS-2: tirzepatide was compared directly with semaglutide in people with type 2 diabetes, at a lower semaglutide dose than the obesity regimen.
2022 - SURMOUNT-1: tirzepatide’s placebo-controlled obesity results were published. Coskun et al. also published the LY3437943/retatrutide triple-receptor development work.
2023 - retatrutide phase 2: the 48-week obesity trial was NCT04881760, not TRIUMPH-2.
2026 - published phase 3 evidence: TRANSCEND-T2D-1 was published for people with type 2 diabetes, and TRIUMPH-1 and TRIUMPH-2 publications appeared on 29 September 2026. TRIUMPH-2 enrolled adults with obesity and type 2 diabetes. Investigational development is separate from regulatory approval.
Comparative Research Efficacy in Published Trials
| Trial | Population and duration | Reported mean body-weight change |
|---|---|---|
| STEP-1, semaglutide | Adults without diabetes; 68 weeks | −14.9% versus −2.4% placebo |
| SURMOUNT-1, tirzepatide | Adults without diabetes; 72 weeks | −15.0% to −20.9% across dose groups versus −3.1% placebo |
| Retatrutide phase 2, NCT04881760 | Adults with obesity; 48 weeks | Up to −24.2% in the highest dose group versus −2.1% placebo |
| TRIUMPH-1 phase 3, retatrutide | Adults with obesity without diabetes; 80 weeks | Treatment-regimen estimand: −17.6% to −25.0% across dose groups versus −3.9% placebo |
| TRIUMPH-2 phase 3, retatrutide | Adults with obesity and type 2 diabetes; 80 weeks | Treatment-regimen estimand: −11.9% to −18.8% across dose groups versus −5.1% placebo |
At 24 weeks, the phase 2 publication reported 17.5% in the highest dose group; time point and treatment group must be retained with each numerical result. These are trial-arm results, not a recommended regimen.
TRIUMPH-1 randomized 2,339 participants without diabetes; TRIUMPH-2 randomized 1,152 with type 2 diabetes. Both tested the same triple-receptor agonist for 80 weeks, yet their highest-group treatment-regimen weight changes were −25.0% and −18.8%. Receptor count was identical, so it cannot explain that difference by itself.
Cross-trial differences do not establish that adding one receptor necessarily causes a larger clinical benefit: populations, dose escalation, durations, estimands and comparators differ. Use a direct matched trial for a comparative conclusion. SURPASS-2 directly compared tirzepatide with semaglutide 1 mg in type 2 diabetes; it does not answer every obesity-dose comparison.
Safety Profiles in Published Research Literature
Gastrointestinal adverse events were common in the cited clinical programs, and the retatrutide phase 2 trial reported dose-related heart-rate increases. Safety conclusions should remain tied to the tested population, formulation and duration.
Trial evidence does not justify a blanket assurance about rare pancreatitis or thyroid-cancer outcomes across every agonist. For an approved product, use its current label; for an investigational molecule, use the actual trial safety report and protocol. A research-grade vial does not inherit the pharmaceutical product’s safety evidence.
For Research Peptide Users
A research-grade preparation must be identified independently of the clinical compound’s history. “GLP-3” is not an established endogenous hormone or a unique scientific molecular name. A catalogue may use it for retatrutide or another material; the sequence, molecular form and lot report determine which one is supplied.
Inspect the GLP-3 listing and its current lot report before assigning a paper’s mechanism to that material. Research quality documentation is separate from clinical authorization.
Conclusion
The receptor profiles differ, but a cross-trial percentage is not a controlled ranking of the molecules. Match the population, duration, comparator and estimand before drawing a comparative conclusion. Retatrutide phase 3 results are now published; publication is distinct from approval.
For a laboratory product labelled GLP-3, check the exact molecular identity and lot documentation. An informal name does not establish a separate analogue, and a research vial is not a pharmaceutical formulation.
Research source
Source GLP-3 for your research
Compare available sizes and check the matching batch certificate before ordering.
View productFrequently Asked Questions
What is the structural difference between Tirzepatide and Semaglutide?
Semaglutide is a 31-amino-acid GLP-1 analog with a C18 fatty-diacid albumin-binding modification, derived from native human GLP-1. Tirzepatide is a 39-amino-acid engineered peptide combining structural features of native GIP with GLP-1-like substitutions and a C20 fatty-diacid linker. Tirzepatide binds and activates both the GIP and GLP-1 receptors, while semaglutide is selective for GLP-1R. The two are different molecules engineered by different research groups.
Is Retatrutide approved for human use?
As checked on 5 October 2026, the cited current trial publications describe retatrutide as investigational. Published phase 3 results now exist, including September 2026 TRIUMPH publications, but publication or trial completion is not regulatory approval.
Can these compounds be used interchangeably in research models?
No - they have different receptor-binding profiles and would be expected to produce different downstream signaling in any model that distinguishes GLP-1, GIP, and glucagon receptor activation. For research questions about a specific receptor pathway, the appropriate selective tool should be used. For questions about multi-receptor agonism, comparative studies typically use multiple compounds with characterized receptor profiles rather than substituting one for another.
How does a product labelled GLP-3 relate to these compounds?
“GLP-3” is an informal commercial label, not a unique molecular identifier. It may refer to retatrutide or a different material. Use the supplied sequence, modifications and lot report to determine identity; the label alone cannot establish that it is a distinct analogue. Retatrutide’s published targets are GLP-1, GIP and glucagon receptors.
Why did researchers add GIP receptor activity to GLP-1?
The published research rationale, articulated in the Coskun et al. (2018) and Finan et al. (2013) mechanism papers, is that GIPR and GLP-1R are distinct receptors with overlapping β-cell signaling, including cAMP, and potentially complementary effects, and that GIP signaling on adipocytes may complement GLP-1's central appetite-regulatory effects in metabolic models. The preclinical comparisons support investigating joint receptor activation. Improved outcomes for a dual agonist do not quantify an isolated GIP contribution in people.
Why did Retatrutide add glucagon receptor activity?
The published rationale, drawn from Day et al. (2009) and the Knerr / Coskun mechanism papers, is that joint glucagon/GLP-1 receptor activation reduced food intake and increased whole-body energy expenditure in the tested rodent models, and that combining glucagon agonism with GLP-1 agonism - which suppresses glucagon's hyperglycemic effects via insulinotropic action - was theorized to dissociate glucagon's metabolic from glycemic effects in research-model contexts. Coskun et al. (2022) tested triple-receptor activity and metabolic responses in defined cell, mouse and early clinical studies; later trial weight changes do not by themselves isolate a hepatic mechanism.
Are any of these compounds available as research peptides from Baltic BioLabs?
Compare the current catalogue and the lot report for the material being considered. The GLP-3 listing is relevant to triple-agonist research, but a trade name is not enough to establish molecular identity or equivalence to a clinical formulation.
Scientific References
- Wilding et al. 2021. STEP-1. PMID: 33567185 - Primary source[PubMed Reference]
- Frias et al. 2021. SURPASS-2. PMID: 34170647 - Primary source[PubMed Reference]
- Jastreboff et al. 2022. SURMOUNT-1. PMID: 35658024 - Primary source[PubMed Reference]
- Coskun et al. 2022. Triple-receptor LY3437943 mechanism. PMID: 35985340 - Primary source[PubMed Reference]
- Jastreboff et al. 2023. Retatrutide phase 2. PMID: 37366315 - Primary source[PubMed Reference]
- 2026. TRANSCEND-T2D-1 phase 3. PMID: 42250575 - Primary source[PubMed Reference]
- 2026. TRIUMPH-1 phase 3. DOI: 10.1056/NEJMoa2604169 - Primary source
- Bellido et al. 2026. TRIUMPH-2 phase 3. PMID: 42810372 - Primary source[PubMed Reference]
- Lau et al. 2015. Semaglutide design and native GLP-1 residue numbering. PMID: 26308095 - Primary source[PubMed Reference]
- Coskun et al. 2018. LY3298176/tirzepatide dual-agonist discovery and cell/mouse/early clinical experiments. PMID: 30473097 - Primary source[PubMed Reference]
- Day et al. 2009. Glucagon/GLP-1 co-agonists in rodent obesity models. PMID: 19597507 - Primary source[PubMed Reference]
- EMA. Injectable semaglutide product information, section 5.2: clinical semaglutide PK - Primary source
- EMA. Oral semaglutide product information, section 5.2: formulation-dependent oral semaglutide absorption - Primary source
- EMA. Tirzepatide product information, section 5.2: clinical tirzepatide PK - Primary source
